CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SCOLR Pharma Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SCOLR Pharma Inc.
Suite 44, 13400 NE 20th Street,
Phone: (425) 368-1050p:425 368-1050 BELLEVUE, WA  98005  United States Fax: (302) 636-5454f:302 636-5454
SCOLR Pharma, Inc. ceased its business operations on March 1, 2013. The cessation of operations may constitute an event of default under the Company’s outstanding 8% Senior Secured Convertible Debentures due June, 2013. The Company has $2,545,200 principal amount outstanding under the debentures. The Debentures are secured by all the Company’s assets pursuant to a Security Agreement dated June 16, 2011 among the Company and CSC Trust Company of Delaware as collateral agent (the “Security Agreement”). Upon certain events of default, the holders of the Debentures may be entitled to accelerate the Company’s obligations under the Debentures and exercise available remedies under the Security Agreement. Following an event of default, interest on the Debentures accrues at a rate of 18% per annum.
This company is no longer actively traded on any major stock exchange.
Business Summary
SCOLR Pharma, Inc. is a specialty pharmaceutical company that combines formulation experience and knowledge with its Controlled Delivery Technology (CDT) platforms to develop and commercialize prescription, over-the-counter (OTC), and nutritional products. The Company has developed multiple private label extended release nutritional products incorporating its formulation technology for commercialization in the United States and Canada. Its lead drug product candidate is a 12 hour extended release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201112/31/2010YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Carl J.Johnson 62 9/24/2010 9/24/2010
President, Chief Executive Officer Stephen J.Turner 40 8/28/2009
Director Michael N.Taglich 45 9/24/2010 1/1/2003
4 additional Officers and Directors records available in full report.

Business Names
Business Name
SCLL
SCOLR INC
SCOLR, Inc.

General Information
Number of Employees: 6 (As of 12/31/2010)
Outstanding Shares: 49,816,073 (As of 9/30/2011)
Shareholders: 49,816
Stock Exchange: OTC
Federal Tax Id: 911689591
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023